| Followers | 79 |
| Posts | 3015 |
| Boards Moderated | 0 |
| Alias Born | 12/04/2020 |
Thursday, July 06, 2023 11:59:40 AM
Bucillamine is dead .... over .... just like we all knew months ago. Question is, can this company shift back to being a psychedelic innovator and actually do something. To be honest, based on how bad the CEO effed up the Bucillamine clinical trial, I don't have much faith. Never seen a bigger foul up.
Recent RVVTF News
- Revive Therapeutics Announces Strategic Expansion of Bucillamine Program Across Infectious Diseases, Defence and Biothreat Medical Countermeasures • ACCESS Newswire • 05/20/2026 11:45:00 AM
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
